CA85935/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2001	2
2002	1
2003	2
2004	2
2005	1
2006	2
2007	1
2008	1
2009	1
2010	3
2011	4
2012	2
2013	2
2022	0

1

New insights into mechanisms of resistance to microtubule inhibitors.

Ganguly A, Cabral F. Ganguly A, et al. Biochim Biophys Acta. 2011 Dec;1816(2):164-71. doi: 10.1016/j.bbcan.2011.06.001. Epub 2011 Jun 29. Biochim Biophys Acta. 2011. PMID: 21741453 Free PMC article. Review.

2

Control of MCAK degradation and removal from centromeres.

Ganguly A, Bhattacharya R, Cabral F. Ganguly A, et al. Cytoskeleton (Hoboken). 2012 May;69(5):303-11. doi: 10.1002/cm.21026. Epub 2012 Apr 3. Cytoskeleton (Hoboken). 2012. PMID: 22422706 Free PMC article.

3

Human mutations that confer paclitaxel resistance.

Yin S, Bhattacharya R, Cabral F. Yin S, et al. Mol Cancer Ther. 2010 Feb;9(2):327-35. doi: 10.1158/1535-7163.MCT-09-0674. Epub 2010 Jan 26. Mol Cancer Ther. 2010. PMID: 20103599 Free PMC article.

4

Paclitaxel resistance by random mutagenesis of α-tubulin.

Yin S, Zeng C, Hari M, Cabral F. Yin S, et al. Cytoskeleton (Hoboken). 2013 Dec;70(12):849-62. doi: 10.1002/cm.21154. Epub 2013 Nov 15. Cytoskeleton (Hoboken). 2013. PMID: 24155014 Free article.

5

Mutations affecting beta-tubulin folding and degradation.

Wang Y, Tian G, Cowan NJ, Cabral F. Wang Y, et al. J Biol Chem. 2006 May 12;281(19):13628-13635. doi: 10.1074/jbc.M513730200. Epub 2006 Mar 22. J Biol Chem. 2006. PMID: 16554299 Free PMC article.

6

Paclitaxel resistance in cells with reduced beta-tubulin.

Wang Y, Cabral F. Wang Y, et al. Biochim Biophys Acta. 2005 Jun 30;1744(2):245-55. doi: 10.1016/j.bbamcr.2004.12.003. Epub 2005 Jan 5. Biochim Biophys Acta. 2005. PMID: 15950754 Free article.

7

Paclitaxel-dependent cell lines reveal a novel drug activity.

Ganguly A, Yang H, Cabral F. Ganguly A, et al. Mol Cancer Ther. 2010 Nov;9(11):2914-23. doi: 10.1158/1535-7163.MCT-10-0552. Epub 2010 Oct 26. Mol Cancer Ther. 2010. PMID: 20978163 Free PMC article.

8

Microtubule dynamics control tail retraction in migrating vascular endothelial cells.

Ganguly A, Yang H, Zhang H, Cabral F, Patel KD. Ganguly A, et al. Mol Cancer Ther. 2013 Dec;12(12):2837-46. doi: 10.1158/1535-7163.MCT-13-0401. Epub 2013 Oct 9. Mol Cancer Ther. 2013. PMID: 24107446 Free PMC article.

9

Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance.

Yin S, Zeng C, Hari M, Cabral F. Yin S, et al. Pharm Res. 2012 Nov;29(11):2994-3006. doi: 10.1007/s11095-012-0794-5. Epub 2012 Jun 6. Pharm Res. 2012. PMID: 22669706

10

Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration.

Ganguly A, Yang H, Cabral F. Ganguly A, et al. Oncotarget. 2011 May;2(5):368-77. doi: 10.18632/oncotarget.250. Oncotarget. 2011. PMID: 21576762 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results